This table lists published NICE technology appraisals. The list can be sorted by title (alphabetically), issue date and review date. You can also:
- click the appraisal title for full details
- click a column heading to sort the list by that column
Please note that the 'review date' is not the date when a review of it the appraisal starts, but the date NICE consults on a proposal for reviewing it. There is no guarantee that at the review date, a review will be undertaken. Appraisals which have been considered for review and where the decision has been not to carry out a review at this time are listed in static technology appraisals.
More information on the published appraisals list.
For technology appraisal guidance organised by category, use Find guidance in the main header area above.
Searching for specific technology appraisal guidance?
Published appraisals
|
Ref |
Title |
Date Issued |
Review |
| TA286 |
Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal) (TA286)
|
May 2013 |
TBC |
| TA285 |
Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285)
|
May 2013 |
Jun 2016 |
| TA284 |
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
|
May 2013 |
Apr 2016 |
| TA283 |
Macular oedema (retinal vein occlusion) - ranibizumab (TA283)
|
May 2013 |
TBC |
| TA282 |
Idiopathic pulmonary fibrosis - pirfenidone (TA282)
|
Apr 2013 |
TBC |
| TA281 |
Gout - canakinumab (terminated appraisal) (TA281)
|
Apr 2013 |
TBC |
| TA280 |
Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) (TA280)
|
Apr 2013 |
TBC |
| TA279 |
Vertebral fractures - vertebroplasty and kyphoplasty (TA279)
|
Apr 2013 |
TBC |
| TA278 |
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) (TA278)
|
Apr 2013 |
TBC |
| TA277 |
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)
|
Mar 2013 |
TBC |
| TA276 |
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
|
Mar 2013 |
TBC |
| TA275 |
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)
|
Feb 2013 |
TBC |
| TA274 |
Macular oedema (diabetic) - ranibizumab (TA274)
|
Feb 2013 |
Feb 2015 |
| TA273 |
Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
|
Jan 2013 |
TBC |
| TA272 |
Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
|
Jan 2013 |
TBC |
| TA271 |
Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271)
|
Jan 2013 |
Nov 2015 |
| TA270 |
Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
|
Dec 2012 |
TBC |
| TA269 |
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)
|
Dec 2012 |
Nov 2014 |
| TA268 |
Melanoma (stage III or IV) - ipilimumab (TA268)
|
Dec 2012 |
Nov 2014 |
| TA267 |
Chronic heart failure - ivabradine (TA267)
|
Nov 2012 |
Nov 2015 |
This page was last updated: 12 June 2013